k141_55195_5	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	37.2	250	240	255	8.84e-45	149
k141_55195_5	SARG|gb|ADZ12699.1|ARO:3005091|RanA	33.9	242	240	258	2.59e-41	140
k141_2574_4	megares|MEG_5400|Drugs|beta-lactam|Penicillin_binding_protein|PBP2_1	32.7	588	636	633	2.28e-95	305
k141_2574_34	NCBI|AKC61310.1|1|1|cplR|cplR|target_protection|1|CLINDAMYCIN/LINCOMYCIN/RETAPAMULIN/VIRGINIAMYCIN|LINCOSAMIDE/PLEUROMUTILIN/STREPTOGRAMIN|ABC-F_type_ribosomal_protection_protein_CplR|AMR|multidrug	27.2	235	272	552	1.51e-15	75.1
k141_2574_34	SARG|gi|445996708|ref|WP_000074563.1|	22.5	231	272	309	7.82e-13	66.2
k141_2574_34	SARG|gi|507023808|ref|WP_016095885.1|	22.5	231	272	309	4.84e-12	63.9
k141_2574_34	SARG|gi|507055561|ref|WP_016126482.1|	21.8	229	272	309	6.56e-12	63.5
k141_2574_34	SARG|ZP_04081918	22.1	222	272	306	8.72e-12	63.2
k141_2574_34	SARG|gi|488053456|ref|WP_002124853.1|	22.1	231	272	309	8.87e-12	63.2
k141_2574_34	SARG|gi|488067981|ref|WP_002139378.1|	22.1	231	272	309	1.20e-11	62.8
k141_2574_34	SARG|gi|487936534|ref|WP_002010000.1|	22.1	231	272	309	1.20e-11	62.8
k141_2574_34	SARG|gi|488068784|ref|WP_002140181.1|	22.1	231	272	309	1.20e-11	62.8
k141_2574_34	SARG|gi|447057510|ref|WP_001134766.1|	22.1	231	272	309	1.20e-11	62.8
k141_82908_8	SARG|gb|AET10445.1|ARO:3004033|tetB(46)	27.5	513	545	578	6.35e-54	191
k141_82908_8	SARG|gi|663155409|ref|WP_030194633.1|	26.5	529	545	605	1.55e-42	159
k141_82908_8	SARG|gi|664538723|ref|WP_031054357.1|	26.5	529	545	605	1.55e-42	159
k141_82908_8	SARG|gi|663330365|ref|WP_030329892.1|	26.5	529	545	607	1.59e-42	159
k141_82908_8	SARG|gi|664194237|ref|WP_030727956.1|	26.5	529	545	605	2.12e-42	159
k141_82908_8	SARG|gi|662175949|ref|WP_030118884.1|	26.5	529	545	605	2.90e-42	159
k141_82908_8	SARG|gi|664317010|ref|WP_030845774.1|	26.5	529	545	605	3.96e-42	158
k141_82908_8	SARG|gi|663286402|ref|WP_030292859.1|	26.5	529	545	605	3.96e-42	158
k141_82908_8	SARG|gi|663342223|ref|WP_030341347.1|	26.5	529	545	605	3.96e-42	158
k141_82908_8	SARG|gi|759527374|ref|WP_043247487.1|	26.5	529	545	605	3.96e-42	158
k141_82908_41	SARG|gb|AAC75314.1|ARO:3003578|pmrF	30.1	306	312	322	1.26e-45	156
k141_82908_42	SARG|gb|CDO12042.1|ARO:3005053|ArnT	30.5	347	559	551	8.55e-39	148
k141_108278_11	NCBI|WP_000163435.1|1|1|mupA|mupA|insensitivity|2|mupirocin|mupirocin|mupirocin-resistant_isoleucine--tRNA_ligase_MupA|AMR|mupirocin	25.2	254	646	1024	1.24e-09	60.5
k141_108278_11	megares|MEG_4089|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	25.2	254	646	1024	1.24e-09	60.5
k141_108278_11	megares|MEG_4090|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	27.3	256	646	1024	1.24e-09	60.5
k141_108278_11	SARG|gb|CAA53189|ARO:3000521|mupA	27.3	256	646	1024	1.24e-09	60.5
k141_108278_11	megares|MEG_4091|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPB_1	26.2	275	646	1033	3.33e-08	55.8
k141_108278_11	SARG|gb|AEY83581|ARO:3000510|mupB	26.2	275	646	1033	3.33e-08	55.8
k141_108278_11	megares|MEG_3295|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|ILES_1	23.8	286	646	1107	6.86e-07	51.6
k141_108278_11	SARG|gb|ADP36409.1|ARO:3003730|Bifidobacteria	23.8	286	646	1107	6.86e-07	51.6
k141_60046_45	NCBI|WP_050824634.1|1|1|tet(O)|tet(O)|target_protection|2|TETRACYCLINE|TETRACYCLINE|tetracycline_resistance_ribosomal_protection_protein_Tet(O)|AMR|tetracycline	36.6	153	398	639	3.47e-16	79.3
k141_60046_46	SARG|NP_348076	28.2	677	691	652	1.69e-82	273
k141_60046_46	SARG|L42544.gene.p01	27.3	673	691	651	6.25e-82	271
k141_60046_46	SARG|AAV80410	27.2	673	691	651	4.58e-81	269
k141_60046_46	SARG|YP_002850805	27.6	674	691	652	4.68e-81	269
k141_60046_46	megares|MEG_7175|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	28.6	678	691	639	2.57e-80	267
k141_60046_46	SARG|ABF69686	28.3	678	691	639	6.95e-80	266
k141_60046_46	SARG|AY485126.gene.p01	28.2	678	691	639	9.69e-80	265
k141_60046_46	megares|MEG_7174|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	28.2	678	691	629	1.08e-79	265
k141_60046_46	ResF|tet(O/W)_2_AM889119_1	28.2	678	691	639	1.35e-79	265
k141_60046_46	megares|MEG_7163|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	28.2	678	691	629	2.10e-79	264
k141_60046_51	CARD|gb|BAD59497.1|ARO:3000501|rpoB2	56.4	1195	1231	1162	0.0	1263
k141_60046_51	CARD|gb|WP_041777404.1|ARO:3004480|Bado_rpoB_RIF	54.0	1205	1231	1186	0.0	1223
k141_60046_51	megares|MEG_8674|Drugs|Rifampin|Rifampin-resistant_beta-subunit_of_RNA_polymerase_RpoB|RPOB_1	54.0	1205	1231	1186	0.0	1223
k141_34859_5	SARG|gb|CDO12042.1|ARO:3005053|ArnT	29.3	331	520	551	1.35e-29	121
k141_34859_25	SARG|AUI09862.1	45.1	277	276	287	1.36e-78	238
k141_34859_25	SARG|gi|754661150|ref|WP_042043527.1|	33.5	254	276	271	4.11e-40	139
k141_34859_25	SARG|gi|553729091|ref|WP_023063817.1|	33.5	254	276	271	8.13e-40	138
k141_34859_25	SARG|gi|499290101|ref|WP_010981367.1|	33.5	254	276	283	1.53e-39	138
k141_34859_25	SARG|gi|550552396|ref|WP_022631488.1|	33.5	254	276	271	2.26e-39	137
k141_34859_25	SARG|gi|487670925|ref|WP_001756235.1|	33.1	254	276	271	3.17e-39	137
k141_34859_25	SARG|gi|1028099083|ref|WP_063855540.1|	33.1	254	276	271	4.46e-39	136
k141_34859_25	SARG|gi|835825825|ref|WP_047670793.1|	33.5	254	276	271	4.46e-39	136
k141_34859_25	SARG|gb|AAL59753.1|ARO:3000412|sul2	33.1	254	276	271	6.27e-39	136
k141_34859_25	SARG|gi|771529592|ref|WP_045178654.1|	33.1	254	276	271	6.27e-39	136
k141_34859_69	NCBI|WP_252944138.1|1|1|almE|almE||2|COLISTIN|COLISTIN|lipid_A_modification_system_glycine--protein_ligase_AlmE|AMR|peptide	24.3	428	471	556	1.86e-11	65.1
k141_23501_4	CARD|gb|BAB41874.1|ARO:3000815|mgrA	29.8	141	152	147	8.57e-22	84.3
k141_23501_18	SARG|NP_348076	26.7	678	689	652	9.28e-74	249
k141_23501_18	SARG|L42544.gene.p01	24.7	665	689	651	1.07e-58	208
k141_23501_18	SARG|AAV80410	24.5	665	689	651	5.29e-58	206
k141_23501_18	SARG|FN594949.1.gene24.p01	24.7	669	689	640	2.65e-52	190
k141_23501_18	SARG|Q02652	24.9	668	689	639	2.18e-39	153
k141_89907_12	megares|MEG_4090|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	33.1	807	932	1024	3.23e-130	416
k141_89907_12	SARG|gb|CAA53189|ARO:3000521|mupA	33.1	807	932	1024	3.23e-130	416
k141_89907_12	NCBI|WP_000163435.1|1|1|mupA|mupA|insensitivity|2|mupirocin|mupirocin|mupirocin-resistant_isoleucine--tRNA_ligase_MupA|AMR|mupirocin	33.1	807	932	1024	4.51e-130	416
k141_89907_12	megares|MEG_4089|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	33.1	807	932	1024	4.51e-130	416
k141_89907_12	megares|MEG_4091|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPB_1	30.8	890	932	1033	1.49e-129	415
k141_89907_12	SARG|gb|AEY83581|ARO:3000510|mupB	30.8	890	932	1033	1.49e-129	415
k141_69394_11	NCBI|WP_063856408.1|1|1|tet(Q)|tet(Q)|target_protection|2|TETRACYCLINE|TETRACYCLINE|tetracycline_resistance_ribosomal_protection_protein_Tet(Q)|AMR|tetracycline	26.4	329	605	654	1.93e-25	110
k141_69394_11	megares|MEG_7182|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETQ_1	26.4	329	605	670	2.01e-25	110
k141_69394_11	SARG|AAB51122	26.4	329	605	670	2.01e-25	110
k141_69394_11	SARG|Q52360	27.4	329	605	641	2.47e-25	109
k141_69394_11	SARG|P70882	27.4	329	605	641	2.47e-25	109
k141_69394_11	SARG|BAD46890	27.4	329	605	657	2.58e-25	109
k141_69394_11	SARG|Q08425	26.4	329	605	641	3.28e-25	109
k141_69394_11	megares|MEG_7181|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETQ_1	26.4	329	605	657	3.44e-25	109
k141_69394_11	SARG|Z21523.gene.p01	26.4	329	605	657	3.44e-25	109
k141_69394_11	NCBI|WP_063856409.1|1|1|tet(Q)|tet(Q)|target_protection|2|TETRACYCLINE|TETRACYCLINE|tetracycline_resistance_ribosomal_protection_protein_Tet(Q)|AMR|tetracycline	26.0	335	605	641	4.36e-25	108
k141_92284_2	NCBI|WP_063856698.1|1|1|vanH-Ac1|vanH-Ac1|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-Ac1|AMR|glycopeptide	37.6	255	322	351	9.66e-36	131
k141_92284_2	NCBI|WP_063856700.1|1|1|vanH-Ao2|vanH-Ao2|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-Ao2|AMR|glycopeptide	35.6	253	322	343	1.61e-35	130
k141_92284_2	NCBI|WP_063856699.1|1|1|vanH-Ao1|vanH-Ao1|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-Ao1|AMR|glycopeptide	35.6	253	322	348	1.77e-35	130
k141_92284_2	SARG|AAY52004	34.9	255	322	322	2.85e-35	129
k141_92284_2	SARG|DQ018711.1.gene4.p01	34.1	279	322	322	7.75e-35	128
k141_92284_2	SARG|AF155139.2.gene6.p01	34.4	253	322	322	2.93e-34	126
k141_92284_2	megares|MEG_7399|Drugs|Glycopeptide|VanA-type_resistance_protein|VANHA_1	39.0	228	322	237	3.16e-34	124
k141_92284_2	SARG|gi|746609237|ref|WP_039635344.1|	34.0	253	322	322	2.16e-33	124
k141_92284_2	SARG|gi|737310392|ref|WP_035293250.1|	33.3	279	322	323	2.20e-33	124
k141_92284_2	NCBI|WP_063856705.1|1|1|vanH-D|vanH-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-D|AMR|glycopeptide	33.5	254	322	323	2.20e-33	124
k141_92284_26	CARD|gb|BAB36671.1|ARO:3000832|evgA	26.8	205	207	204	1.51e-25	97.4
k141_92284_26	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	28.2	110	207	231	5.00e-10	56.2
k141_92284_26	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	27.0	115	207	232	2.12e-08	51.6
k141_92284_26	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	27.0	115	207	232	2.12e-08	51.6
k141_92284_26	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	32.2	115	207	228	3.30e-07	48.1
k141_92284_26	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	24.8	141	207	233	3.40e-07	48.1
k141_92284_26	CARD|gb|ADM92605.1|ARO:3000553|adeR	24.8	105	207	247	3.68e-07	48.1
k141_92284_26	CARD|gb|ATC67679.1|ARO:3000838|arlR	26.7	116	207	219	5.73e-07	47.4
k141_92284_26	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	25.5	110	207	232	8.45e-07	47.0
k141_92284_26	NCBI|WP_005228837.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	27.0	178	207	231	1.54e-06	46.2
k141_73933_6	SARG|gb|CBL80435.1|ARO:3002869|dfrK	36.6	161	166	163	5.80e-30	106
k141_73933_6	NCBI|WP_012779617.1|1|1|dfrK|dfrK|insensitivity|2|diaminopyrimidine|diaminopyrimidine|diaminopyrimidine-resistant_dihydrofolate_reductase_DfrK|AMR|diaminopyrimidine	36.6	161	166	163	5.80e-30	106
k141_73933_6	NCBI|WP_031775848.1|1|1|dfrK|dfrK|insensitivity|2|diaminopyrimidine|diaminopyrimidine|diaminopyrimidine-resistant_dihydrofolate_reductase_DfrK|AMR|diaminopyrimidine	36.6	161	166	163	5.80e-30	106
k141_73933_6	SARG|CAE53424	37.0	165	166	169	9.63e-30	105
k141_73933_6	SARG|CAL48457	38.2	170	166	183	9.84e-30	106
k141_73933_6	megares|MEG_8062|Drugs|Trimethoprim|Dihydrofolate_reductase|DFRA_1	37.3	169	166	195	3.75e-29	105
k141_73933_6	SARG|gb|WP_000949574.1|ARO:3005348|DfrA36	37.3	169	166	195	3.75e-29	105
k141_73933_6	SARG|gb|BAE15963.1|ARO:3002868|dfrG	34.8	161	166	165	9.72e-29	103
k141_73933_6	SARG|gb|AAO04716.1|ARO:3002865|dfrC	36.6	161	166	161	2.47e-28	102
k141_73933_6	NCBI|WP_000175735.1|1|1|dfrS1|dfrC|insensitivity|2|diaminopyrimidine|diaminopyrimidine|diaminopyrimidine-resistant_dihydrofolate_reductase_DfrS1|AMR|diaminopyrimidine	36.6	161	166	161	3.48e-28	101
k141_73933_15	SARG|gb|APB03219.1|ARO:3003986|TaeA	23.8	227	216	648	2.02e-11	61.6
k141_73933_21	NCBI|WP_063856705.1|1|1|vanH-D|vanH-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-D|AMR|glycopeptide	32.3	164	319	323	6.47e-15	73.2
k141_73933_21	SARG|gi|740152780|ref|WP_037997109.1|	25.4	228	319	322	1.59e-14	72.0
k141_73933_29	NCBI|WP_005813024.1|1|1|vanW-I|vanW-I||2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_accessory_protein_VanW-I|AMR|glycopeptide	38.8	152	509	373	5.87e-26	108
k141_41861_13	SARG|NP_631702	27.5	360	399	392	2.66e-19	87.8
k141_41861_13	SARG|X59968.1.gene1.p01	27.5	360	399	392	3.59e-19	87.4
k141_41861_13	SARG|YP_251195	23.7	355	399	391	4.67e-15	75.1
k141_41861_13	SARG|AF024666.2.gene33.p01	23.7	355	399	391	4.67e-15	75.1
k141_41861_13	SARG|gi|2708772|gb|AAB96371.1|	23.4	355	399	391	1.12e-14	73.9
k141_41861_13	SARG|NP_044444	23.4	355	399	391	1.50e-14	73.6
k141_41861_16	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	33.0	112	197	228	1.31e-12	63.2
k141_41861_16	CARD|gb|ADM92605.1|ARO:3000553|adeR	31.6	117	197	247	6.88e-08	50.1
k141_41861_16	CARD|gb|BAB36671.1|ARO:3000832|evgA	23.9	113	197	204	5.27e-06	44.3
k141_87867_24	SARG|WP_000345069.1	32.6	408	446	434	8.40e-66	216
k141_87867_26	SARG|gb|AAV85982.1|ARO:3000535|macB	29.5	220	492	644	1.05e-19	91.3
k141_87867_26	SARG|gi|488306124|ref|WP_002376519.1|	26.3	224	492	498	4.12e-06	48.1
k141_87867_28	SARG|P42332	28.1	231	272	306	1.58e-18	82.4
k141_87867_28	megares|MEG_1213|Drugs|Bacitracin|Bacitracin_ABC_transporter|BCRA_1	28.1	231	272	306	1.58e-18	82.4
k141_87867_28	SARG|gi|510143239|gb|AGN36970.1|	28.1	231	272	313	1.71e-18	82.4
k141_87867_28	SARG|ABB80128	28.1	231	272	306	4.09e-18	81.3
k141_87867_28	SARG|AAD21213	28.1	231	272	306	5.62e-18	80.9
k141_87867_28	SARG|gb|SOX29786.1|ARO:3004730|tva(A)	29.3	215	272	505	2.29e-13	68.6
k141_87867_28	NCBI|WP_014936356.1|1|1|tva(B)|tva(B)|target_protection|2|TIAMULIN|PLEUROMUTILIN|ABC-F_type_ribosomal_protection_protein_Tva(B)|AMR|pleuromutilin	28.8	215	272	504	1.82e-12	65.9
k141_87867_28	ResF|poxtA-Ef_1_WP094899500.1_1	27.9	201	272	538	2.27e-08	53.5
k141_87867_28	megares|MEG_8639|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|POXT_1	27.9	201	272	543	2.28e-08	53.5
k141_87867_28	NCBI|WP_094899500.1|1|1|poxtA-Ef|poxtA-Ef|target_protection|2|CHLORAMPHENICOL/FLORFENICOL/LINEZOLID|OXAZOLIDINONE/PHENICOL|ABC-F_type_ribosomal_protection_protein_PoxtA-Ef|AMR|multidrug	27.9	201	272	543	2.28e-08	53.5
k141_101770_41	SARG|AJ295238.gene.p01	25.9	441	601	639	5.84e-28	117
k141_101770_41	SARG|ABV82120	25.7	440	601	639	5.84e-28	117
k141_101770_41	megares|MEG_7171|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	25.6	441	601	639	7.78e-28	117
k141_101770_41	SARG|ZP_03989103	25.5	440	601	639	1.84e-27	116
k141_101770_41	SARG|ABV82118	25.2	440	601	639	2.46e-27	115
k141_101770_41	megares|MEG_7166|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	26.2	446	601	639	5.82e-27	114
k141_101770_41	SARG|ABN79417	28.0	436	601	639	1.83e-26	113
k141_101770_41	SARG|AAO42740	28.0	436	601	639	2.44e-26	112
k141_101770_41	SARG|AY485126.gene.p01	28.0	436	601	639	2.44e-26	112
k141_101770_41	megares|MEG_7175|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	28.0	436	601	639	2.44e-26	112
k141_99590_6	SARG|gi|696368937|ref|WP_032943949.1|	40.3	238	256	648	1.72e-43	154
k141_99590_6	SARG|gi|851913025|ref|WP_048215946.1|	40.5	237	256	648	2.37e-43	154
k141_99590_6	SARG|gi|696361545|ref|WP_032936694.1|	40.3	238	256	648	2.37e-43	154
k141_99590_6	SARG|gi|489930965|ref|WP_003834285.1|	40.5	237	256	648	2.37e-43	154
k141_99590_6	SARG|gi|936194420|ref|WP_054528571.1|	41.2	238	256	648	3.28e-43	154
k141_99590_6	SARG|gi|489936909|ref|WP_003840216.1|	40.5	237	256	648	3.28e-43	154
k141_99590_6	SARG|gi|507079862|ref|WP_016150620.1|	40.5	237	256	648	3.28e-43	154
k141_99590_6	SARG|gi|949791377|ref|WP_057104572.1|	40.5	237	256	648	3.28e-43	154
k141_99590_6	SARG|YP_002850060	40.5	237	256	648	4.52e-43	153
k141_99590_6	SARG|gi|851922185|ref|WP_048218206.1|	40.5	237	256	648	6.23e-43	153
k141_99590_15	SARG|AAY52004	35.1	271	326	322	1.07e-37	135
k141_99590_15	SARG|NP_878015	35.0	274	326	322	1.50e-37	135
k141_99590_15	NCBI|WP_063856710.1|1|1|vanH-Pt2|vanH-Pt2|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-Pt2|AMR|glycopeptide	34.7	268	326	322	2.17e-36	132
k141_99590_15	SARG|gi|749574782|ref|WP_040203616.1|	32.3	269	326	323	1.24e-33	125
k141_99590_15	SARG|FJ349556.1.gene5.p01	32.9	249	326	326	3.56e-33	124
k141_99590_15	SARG|gi|738848198|ref|WP_036737307.1|	31.4	274	326	323	6.52e-33	123
k141_99590_15	SARG|gi|746609237|ref|WP_039635344.1|	30.6	268	326	322	1.25e-31	119
k141_99590_15	SARG|gi|740152780|ref|WP_037997109.1|	31.2	250	326	322	9.07e-31	117
k141_99590_15	SARG|gi|737310392|ref|WP_035293250.1|	31.0	271	326	323	9.24e-31	117
k141_99590_15	NCBI|WP_063856700.1|1|1|vanH-Ao2|vanH-Ao2|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-Ao2|AMR|glycopeptide	31.7	265	326	343	4.92e-30	115
k141_99590_36	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	40.6	229	236	229	1.03e-53	171
k141_99590_36	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	39.0	228	236	232	2.89e-51	165
k141_99590_36	NCBI|WP_005228837.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	39.2	227	236	231	1.27e-49	161
k141_99590_36	NCBI|WP_222891057.1|1|1|vanR-P|vanR-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-P|AMR|glycopeptide	39.4	231	236	239	4.49e-49	160
k141_99590_36	NCBI|WP_063856728.1|1|1|vanR-N|vanR-N|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-N|AMR|glycopeptide	39.4	231	236	230	6.94e-49	159
k141_99590_36	NCBI|WP_063856725.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	39.2	227	236	231	7.14e-49	159
k141_99590_36	NCBI|WP_034872470.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	39.2	227	236	231	1.01e-48	159
k141_99590_36	NCBI|WP_003126775.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	38.5	226	236	231	2.85e-48	157
k141_99590_36	NCBI|WP_001280781.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	36.4	228	236	231	9.03e-47	154
k141_99590_36	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	39.0	228	236	233	9.55e-47	154
k141_99590_41	NCBI|WP_281052475.1|1|1|mcr-4.9|mcr-4||2|COLISTIN|COLISTIN|phosphoethanolamine--lipid_A_transferase_MCR-4.9|AMR|peptide	23.9	447	607	541	1.92e-18	87.8
k141_32933_4	SARG|CP001581.1.gene725.p01	29.0	414	453	477	1.87e-47	169
k141_32933_29	SARG|gb|APB03219.1|ARO:3003986|TaeA	28.2	234	354	648	2.17e-16	79.3
k141_35459_7	megares|MEG_5409|Drugs|beta-lactam|Penicillin_binding_protein|PBP4B_1	31.1	196	429	434	6.60e-11	62.8
k141_35459_8	NCBI|CZR78671.1|1|1|vanT-Cd|vanT-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT-Cd|AMR|glycopeptide	36.2	373	401	712	6.17e-61	208
k141_35459_8	SARG|gb|ABX54690.1|ARO:3002974|vanTrL	32.2	363	401	366	9.73e-56	186
k141_35459_8	SARG|JF802084.2.gene3.p01	30.8	360	401	700	3.76e-50	178
k141_35459_8	SARG|gi|498467693|ref|WP_010773049.1|	30.6	366	401	700	7.15e-50	177
k141_35459_8	SARG|FJ872411.1.gene43.p01	30.1	366	401	702	1.21e-47	171
k141_35459_8	SARG|AAY67970	29.6	361	401	698	1.60e-47	171
k141_35459_8	SARG|AF162694.1.gene4.p01	29.6	361	401	698	3.03e-47	170
k141_35459_8	SARG|gi|657686198|ref|WP_029487032.1|	29.6	361	401	698	3.03e-47	170
k141_35459_8	NCBI|WP_063856755.1|1|1|vanT-C|vanT-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT-C|AMR|glycopeptide	33.1	329	401	700	3.08e-47	170
k141_35459_8	NCBI|WP_063856756.1|1|1|vanT-C|vanT-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT-C|AMR|glycopeptide	33.7	315	401	700	4.24e-47	170
k141_35459_12	SARG|gb|APB03219.1|ARO:3003986|TaeA	46.5	639	622	648	8.59e-179	520
k141_35459_12	megares|MEG_4318|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	28.0	642	622	655	8.41e-66	226
k141_35459_12	megares|MEG_4316|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	27.7	642	622	655	1.17e-65	226
k141_35459_12	megares|MEG_4304|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	27.7	642	622	655	2.24e-65	225
k141_35459_12	SARG|gb|AKA86814|ARO:3003746|optrA	27.7	642	622	655	2.24e-65	225
k141_35459_12	megares|MEG_4308|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	27.9	642	622	655	5.96e-65	224
k141_35459_12	megares|MEG_4312|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	27.9	642	622	655	1.14e-64	223
k141_35459_12	megares|MEG_4315|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	27.9	642	622	655	1.14e-64	223
k141_35459_12	megares|MEG_4309|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	27.9	642	622	655	1.58e-64	223
k141_35459_12	megares|MEG_4306|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	27.9	642	622	655	1.58e-64	223
k141_8211_11	ResF|erm(A)_3_EU348758_1	25.3	257	286	243	6.30e-15	71.6
k141_8211_11	SARG|L22689.1.gene1.p01	25.2	266	286	257	2.65e-14	70.1
k141_8211_11	megares|MEG_2786|Drugs|MLS|23S_rRNA_methyltransferases|ERMA_1	25.9	170	286	198	5.51e-11	59.7
k141_1846_28	SARG|gb|AAK76137.1|ARO:3000024|patA	27.2	206	347	564	1.13e-11	64.7
k141_1846_28	SARG|gb|AAK76136.1|ARO:3000025|patB	26.0	196	347	588	2.59e-08	54.3
k141_1846_28	SARG|gb|AET10445.1|ARO:3004033|tetB(46)	26.1	199	347	578	3.42e-08	53.9
k141_1846_28	SARG|gi|171851258|emb|CAQ04234.1|	46.6	58	347	483	7.08e-07	49.7
k141_1846_28	SARG|gi|736993687|ref|WP_034989673.1|	44.8	58	347	513	1.71e-06	48.5
k141_1846_28	SARG|AF024666.2.gene6.p01	44.8	58	347	513	1.71e-06	48.5
k141_1846_28	NCBI|AJP12342.1|1|1|cplR|cplR|target_protection|1|CLINDAMYCIN/LINCOMYCIN/RETAPAMULIN/VIRGINIAMYCIN|LINCOSAMIDE/PLEUROMUTILIN/STREPTOGRAMIN|ABC-F_type_ribosomal_protection_protein_CplR|AMR|multidrug	24.6	191	347	550	2.34e-06	48.1
k141_1846_28	NCBI|WP_172065992.1|1|1|vga(F)|vga(F)|target_protection|2|LINCOSAMIDE|LINCOSAMIDE|ABC-F_type_ribosomal_protection_protein_Vga(F)|AMR|lincosamide	24.6	175	347	461	2.85e-06	47.8
k141_1846_28	NCBI|WP_171943877.1|1|1|vga(F)|vga(F)|target_protection|2|LINCOSAMIDE|LINCOSAMIDE|ABC-F_type_ribosomal_protection_protein_Vga(F)|AMR|lincosamide	32.1	81	347	461	3.78e-06	47.4
k141_106902_1	SARG|gi|881076539|ref|WP_048792533.1|	25.1	167	446	388	1.11e-11	65.1
k141_106902_1	SARG|gi|1002473411|ref|WP_061389367.1|	24.0	167	446	385	6.13e-11	62.8
k141_106902_1	SARG|gi|446964076|ref|WP_001041332.1|	24.0	167	446	388	6.20e-11	62.8
k141_106902_1	SARG|gi|658594643|ref|WP_029753517.1|	24.0	167	446	388	6.20e-11	62.8
k141_106902_1	SARG|gi|686123480|ref|WP_031769406.1|	24.1	166	446	388	6.20e-11	62.8
k141_106902_1	SARG|gi|537465395|ref|WP_020977063.1|	24.0	167	446	388	6.20e-11	62.8
k141_106902_1	SARG|gi|686372358|ref|WP_031896405.1|	24.0	167	446	388	6.20e-11	62.8
k141_106902_1	SARG|gi|1031779476|ref|WP_064126793.1|	23.8	168	446	388	8.25e-11	62.4
k141_106902_1	SARG|gi|487135433|ref|WP_001627390.1|	23.5	166	446	388	8.25e-11	62.4
k141_106902_1	SARG|gi|930433773|ref|WP_054194603.1|	24.0	167	446	388	8.25e-11	62.4
k141_106902_5	CARD|gb|CAA79966.1|ARO:3003665|NmcR	29.7	118	309	295	6.47e-08	52.0
k141_106902_24	SARG|gb|APB03220.1|ARO:3003987|VatI	36.0	114	191	210	8.47e-11	57.8
k141_106902_24	SARG|M58472.1.gene1.p01	43.9	57	191	209	6.54e-08	49.7
k141_107018_1	CARD|gb|ABD30512.1|ARO:3000839|arlS	36.3	262	478	451	5.15e-50	176
k141_107018_1	CARD|gb|AEX49906.1|ARO:3003583|basS	31.0	281	478	477	4.46e-30	121
k141_107018_1	NCBI|WP_063856748.1|1|1|vanS-M|vanS-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-M|AMR|glycopeptide	27.0	263	478	370	3.18e-24	102
k141_107018_1	NCBI|WP_011461302.1|1|1|vanS-I|vanS-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-I|AMR|glycopeptide	30.5	226	478	392	7.62e-24	102
k141_107018_1	NCBI|WP_021418927.1|1|1|vanS-G|vanS-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-G|AMR|glycopeptide	28.8	212	478	368	1.42e-23	100
k141_107018_1	NCBI|WP_063856732.1|1|1|vanS-G|vanS-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-G|AMR|glycopeptide	29.7	219	478	367	1.91e-23	100
k141_107018_1	CARD|gb|AAD51347.1|ARO:3003067|smeS	31.6	215	478	467	2.73e-23	101
k141_107018_1	NCBI|WP_006285582.1|1|1|vanS-F|vanS-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-F|AMR|glycopeptide	26.7	240	478	365	7.06e-22	95.9
k141_107018_1	megares|MEG_7514|Drugs|Glycopeptide|VanL-type_regulator|VANSL_1	26.2	248	478	364	5.74e-21	93.2
k141_107018_1	NCBI|WP_063856745.1|1|1|vanS-L|vanS-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-L|AMR|glycopeptide	26.2	248	478	364	5.74e-21	93.2
k141_107018_2	CARD|gb|ATC67679.1|ARO:3000838|arlR	47.7	220	227	219	4.02e-67	205
k141_107018_2	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	41.7	228	227	232	1.51e-51	166
k141_107018_2	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	41.7	228	227	232	1.51e-51	166
k141_107018_2	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	37.8	225	227	228	9.72e-49	158
k141_107018_2	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	40.9	237	227	235	3.35e-48	157
k141_107018_2	NCBI|WP_063856728.1|1|1|vanR-N|vanR-N|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-N|AMR|glycopeptide	39.2	227	227	230	6.54e-47	154
k141_107018_2	NCBI|WP_063856724.1|1|1|vanR-L|vanR-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-L|AMR|glycopeptide	36.3	226	227	231	3.01e-45	149
k141_107018_2	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	37.6	229	227	233	2.53e-44	147
k141_107018_2	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	40.6	224	227	232	6.93e-44	146
k141_107018_2	NCBI|WP_222891057.1|1|1|vanR-P|vanR-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-P|AMR|glycopeptide	35.5	231	227	239	1.67e-43	145
k141_107018_14	SARG|YP_002333394	35.8	243	531	323	1.20e-31	123
k141_107018_14	SARG|AF310956.2.gene5.p01	35.8	243	531	323	1.64e-31	123
k141_107018_14	NCBI|WP_063856701.1|1|1|vanH-B|vanH-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-B|AMR|glycopeptide	35.8	243	531	323	1.64e-31	123
k141_107018_14	SARG|gb|AAB05626.1|ARO:3002943|vanHB	35.4	243	531	323	7.93e-31	121
k141_107018_14	SARG|Q47748	35.0	243	531	323	2.04e-30	120
k141_107018_14	SARG|gi|498515089|ref|WP_010815296.1|	35.0	243	531	323	2.79e-30	119
k141_107018_14	SARG|gi|985522333|ref|WP_060811962.1|	34.6	243	531	323	9.77e-30	118
k141_107018_14	SARG|AAF72362	35.0	243	531	323	1.83e-29	117
k141_107018_14	SARG|KF478993.1.gene2.p01	28.7	282	531	350	3.61e-26	108
k141_107018_14	NCBI|WP_011029109.1|1|1|vanH-Sc|vanH-Sc|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-Sc|AMR|glycopeptide	29.5	251	531	337	7.17e-24	101
k141_107018_18	CARD|gb|AAN28945.1|ARO:3003785|Ctra_murA_FOF	35.3	439	425	444	2.69e-72	233
k141_107018_22	SARG|gb|ADZ12700.1|ARO:3005090|RanB	31.8	245	255	253	2.58e-27	104
k141_107018_23	SARG|gb|ADZ12699.1|ARO:3005091|RanA	31.4	242	251	258	1.91e-44	149
k141_107018_23	SARG|gi|507023808|ref|WP_016095885.1|	29.8	215	251	309	5.25e-34	123
k141_107018_23	SARG|gi|507055561|ref|WP_016126482.1|	29.8	215	251	309	1.44e-33	122
k141_107018_23	SARG|gi|488053456|ref|WP_002124853.1|	29.8	215	251	309	1.44e-33	122
k141_107018_23	SARG|gi|488068784|ref|WP_002140181.1|	29.8	215	251	309	1.44e-33	122
k141_107018_23	SARG|gi|445996719|ref|WP_000074574.1|	28.9	218	251	309	2.02e-33	122
k141_107018_23	SARG|gi|447057510|ref|WP_001134766.1|	29.3	215	251	309	2.02e-33	122
k141_107018_23	SARG|gi|507044560|ref|WP_016115614.1|	29.4	218	251	306	3.72e-33	121
k141_107018_23	SARG|gi|488067981|ref|WP_002139378.1|	29.3	215	251	309	3.95e-33	121
k141_107018_23	SARG|gi|487936534|ref|WP_002010000.1|	29.3	215	251	309	3.95e-33	121
k141_107018_25	SARG|gi|739062736|ref|WP_036934147.1|	30.3	178	561	463	8.91e-11	63.2
k141_107018_25	SARG|gi|559234117|ref|WP_023582764.1|	29.3	188	561	465	1.48e-09	59.3
k141_107018_25	SARG|gi|225204373|gb|EEG86727.1|	27.3	176	561	366	7.75e-08	53.5
k141_107018_25	SARG|gi|857776206|emb|CRL64100.1|	27.8	176	561	462	9.71e-08	53.5
k141_107018_25	SARG|gi|857585365|emb|CRL63509.1|	27.3	176	561	465	9.76e-08	53.5
k141_107018_25	SARG|gi|983380344|ref|WP_060557638.1|	26.1	176	561	465	1.71e-07	52.8
k141_107018_25	SARG|gi|490369843|ref|WP_004249473.1|	26.3	175	561	465	1.71e-07	52.8
k141_107018_25	SARG|gi|516438627|ref|WP_017827539.1|	26.3	175	561	465	2.25e-07	52.4
k141_107018_25	SARG|gi|983376794|ref|WP_060554862.1|	26.3	175	561	465	2.25e-07	52.4
k141_107018_25	SARG|CP004022.1.gene2485.p01	26.3	175	561	471	2.27e-07	52.4
k141_107018_62	SARG|AAB17875	31.8	148	270	274	7.38e-15	71.6
k141_107018_62	SARG|P18644	30.4	148	270	269	1.31e-14	70.9
k141_107018_71	megares|MEG_4091|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPB_1	25.4	786	888	1033	3.78e-86	296
k141_107018_71	SARG|gb|AEY83581|ARO:3000510|mupB	25.4	786	888	1033	3.78e-86	296
k141_107018_71	NCBI|WP_000163435.1|1|1|mupA|mupA|insensitivity|2|mupirocin|mupirocin|mupirocin-resistant_isoleucine--tRNA_ligase_MupA|AMR|mupirocin	23.7	832	888	1024	1.12e-67	243
k141_107018_71	megares|MEG_4089|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	23.7	832	888	1024	1.12e-67	243
k141_107018_71	megares|MEG_4090|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	23.7	832	888	1024	3.78e-67	241
k141_107018_71	SARG|gb|CAA53189|ARO:3000521|mupA	23.7	832	888	1024	3.78e-67	241
k141_107018_76	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	32.7	208	230	232	1.36e-34	122
k141_107018_76	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	32.7	208	230	232	1.36e-34	122
k141_107018_76	CARD|gb|AAG06465.1|ARO:3005063|cprR	36.7	180	230	223	9.24e-33	117
k141_107018_76	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	35.3	207	230	231	2.23e-32	116
k141_107018_76	NCBI|WP_003126775.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	34.1	208	230	231	1.22e-31	114
k141_107018_76	NCBI|WP_063856725.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	32.7	208	230	231	4.78e-31	113
k141_107018_76	NCBI|WP_034872470.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	32.7	208	230	231	6.72e-31	112
k141_107018_76	NCBI|WP_005228837.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	32.7	208	230	231	9.44e-31	112
k141_107018_76	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	31.7	208	230	229	1.27e-30	112
k141_107018_76	megares|MEG_3448|Drugs|Aminoglycosides|Aminoglycoside_efflux_pumps|KDPE_1	34.7	202	230	225	8.85e-30	109
k141_5836_5	SARG|gi|727755142|ref|WP_033862510.1|	25.2	421	449	514	7.74e-25	105
k141_5836_5	SARG|gb|BAJ09383.1|ARO:3003046|qacA	24.9	421	449	514	1.89e-24	104
k141_5836_5	SARG|gi|446545432|ref|WP_000622778.1|	24.5	421	449	514	2.55e-24	104
k141_5836_5	SARG|YP_536864	24.9	421	449	514	2.55e-24	104
k141_5836_5	SARG|AAK38457	24.7	421	449	514	3.43e-24	103
k141_5836_5	SARG|gi|488380213|ref|WP_002449598.1|	24.5	421	449	514	4.61e-24	103
k141_5836_5	SARG|gi|1028097908|ref|WP_063854503.1|	24.7	421	449	514	1.12e-23	102
k141_5836_5	SARG|AAQ10697	24.7	421	449	514	1.12e-23	102
k141_5836_5	SARG|gi|3327943|gb|AAC38780.1|	24.2	421	449	514	1.12e-23	102
k141_5836_5	NCBI|WP_430673474.1|1|1|nms|nms||2|AMIKACIN/CLINDAMYCIN/DOXYCYCLINE/ERYTHROMYCIN/GENTAMICIN/MINOCYCLINE/PLEUROMUTILIN/TETRACYCLINE|aminoglycoside/LINCOSAMIDE/MACROLIDE/PLEUROMUTILIN/TETRACYCLINE|multidrug_efflux_MFS_transporter_Nms|AMR|multidrug	23.6	165	449	374	2.21e-06	48.5
k141_5836_8	SARG|gi|542061059|gb|ERI11611.1|	32.0	178	223	316	3.75e-25	99.4
k141_5836_8	SARG|gi|500448961|gb|EOP61695.1|	29.7	175	223	306	4.50e-22	90.9
k141_5836_8	SARG|gi|500465078|gb|EOP76697.1|	29.7	175	223	306	6.24e-22	90.5
k141_5836_8	SARG|gi|500194536|ref|WP_011867743.1|	29.1	175	223	306	3.19e-21	88.6
k141_5836_8	SARG|ZP_04081918	28.5	179	223	306	4.43e-21	88.2
k141_5836_8	SARG|gi|445996710|ref|WP_000074565.1|	28.6	175	223	309	6.37e-21	87.8
k141_5836_8	SARG|gi|445996719|ref|WP_000074574.1|	27.9	179	223	309	8.82e-21	87.4
k141_5836_8	SARG|gi|447195835|ref|WP_001273091.1|	28.5	179	223	306	2.25e-20	86.3
k141_5836_8	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	28.7	181	223	255	4.00e-20	84.7
k141_5836_8	SARG|gi|447195836|ref|WP_001273092.1|	27.9	179	223	306	5.97e-20	85.1
k141_5836_22	NCBI|WP_050824634.1|1|1|tet(O)|tet(O)|target_protection|2|TETRACYCLINE|TETRACYCLINE|tetracycline_resistance_ribosomal_protection_protein_Tet(O)|AMR|tetracycline	37.4	131	396	639	6.05e-16	78.6
k141_45160_5	SARG|ABO60985	40.9	88	212	289	1.34e-13	67.0
k141_45160_5	SARG|ABO60984	40.9	88	212	289	1.34e-13	67.0
k141_45160_5	SARG|gi|950731935|ref|WP_057495631.1|	38.6	88	212	290	7.89e-12	62.0
k141_45160_5	SARG|EU408349.1.gene1.p01	34.8	92	212	305	4.39e-08	51.2
k141_45160_6	NCBI|AKA30736.1|1|1|cxpE|cxpE||1|CHLORAMPHENICOL|PHENICOL|phenicol_efflux_transporter_CxpE|AMR|phenicol	29.5	227	365	397	1.41e-19	88.2
k141_8919_18	CARD|gb|AAK37618.1|ARO:3005008|TxR	37.9	285	627	318	2.30e-53	184
k141_5950_27	SARG|NP_826974	25.3	182	438	540	4.70e-06	47.8
k141_5950_36	CARD|gb|AAC75137.1|ARO:3000794|mdtC	27.9	1041	1027	1025	4.10e-107	357
k141_5950_36	CARD|gb|AAL14440.1|ARO:3000775|adeB	27.6	1044	1027	1035	4.77e-106	354
k141_5950_36	SARG|gb|BAE06006.1|ARO:3003705|mexN	29.0	1043	1027	1036	6.71e-106	353
k141_5950_36	SARG|ZP_02371789	27.9	1057	1027	1061	7.74e-100	337
k141_5950_36	SARG|ABC36050	27.9	1057	1027	1061	7.74e-100	337
k141_5950_36	SARG|YP_001186705	27.1	1031	1027	1017	1.35e-99	336
k141_5950_36	SARG|ZP_02405550	27.8	1055	1027	1061	2.79e-99	336
k141_5950_36	SARG|YP_001025938	27.8	1055	1027	1061	3.84e-99	335
k141_5950_36	SARG|CAY51926	27.2	1044	1027	1008	4.17e-99	334
k141_5950_36	SARG|YP_792720	26.9	1036	1027	1018	1.79e-98	333
k141_68134_18	SARG|B7LM76	32.6	310	312	660	3.13e-45	161
k141_68134_18	SARG|gi|757781454|ref|WP_043000038.1|	33.9	310	312	660	5.95e-45	160
k141_68134_18	SARG|gi|851899656|ref|WP_048211088.1|	33.2	310	312	660	3.83e-43	155
k141_68134_18	SARG|gi|851917461|ref|WP_048217311.1|	32.6	310	312	660	1.37e-42	154
k141_68134_18	SARG|gi|550713000|ref|WP_022645909.1|	32.3	310	312	660	2.60e-42	153
k141_68134_18	SARG|gi|692997842|ref|WP_032184680.1|	32.3	310	312	660	3.57e-42	153
k141_68134_18	SARG|gi|765458296|ref|WP_044714032.1|	32.6	310	312	660	3.57e-42	153
k141_68134_18	SARG|gi|391316952|gb|EIQ74337.1|	32.6	310	312	660	3.57e-42	153
k141_68134_18	SARG|gi|851981245|ref|WP_048240645.1|	32.3	310	312	660	4.91e-42	152
k141_68134_18	SARG|gi|696375142|ref|WP_032949690.1|	32.3	310	312	660	6.75e-42	152
k141_68134_20	SARG|gb|BAH45481.1|ARO:3002815|clbB	36.4	321	343	343	7.59e-53	176
k141_68134_20	NCBI|WP_111690898.1|1|1|cfr(C)|cfr(C)|target_modification|2|CHLORAMPHENICOL/CLINDAMYCIN/FLORFENICOL/LINEZOLID/STREPTOGRAMIN/TIAMULIN|LINCOSAMIDE/OXAZOLIDINONE/PHENICOL/PLEUROMUTILIN/STREPTOGRAMIN|23S_rRNA_(adenine(2503)-C(8))-methyltransferase_Cfr(C)|AMR|multidrug	34.2	333	343	379	3.90e-51	173
k141_68134_20	megares|MEG_1680|Drugs|MLS|23S_rRNA_methyltransferases|CFR_1	34.5	333	343	416	4.60e-51	174
k141_68134_20	NCBI|WP_032491462.1|1|1|cfr|cfr|target_modification|2|CHLORAMPHENICOL/CLINDAMYCIN/FLORFENICOL/LINEZOLID/STREPTOGRAMIN_B/TIAMULIN/VIRGINIAMYCIN|LINCOSAMIDE/OXAZOLIDINONE/PHENICOL/PLEUROMUTILIN/STREPTOGRAMIN|23S_rRNA_(adenine(2503)-C(8))-methyltransferase_Cfr|AMR|multidrug	33.0	333	343	349	1.36e-46	160
k141_68134_20	SARG|AJ249217.gene.p01	33.0	333	343	349	3.74e-46	159
k141_68134_20	SARG|gb|BAD63613.1|ARO:3002816|clbC	33.0	342	343	350	2.07e-45	157
k141_68134_22	CARD|gb|WKR28567.1|ARO:3007678|IreK	35.8	531	639	718	5.29e-84	277
k141_68134_32	SARG|gb|AAC75314.1|ARO:3003578|pmrF	35.1	94	337	322	1.16e-06	48.5
k141_68134_45	SARG|gb|APB03219.1|ARO:3003986|TaeA	22.2	234	357	648	1.77e-11	64.3
k141_68134_52	CARD|gb|CAA79966.1|ARO:3003665|NmcR	27.1	140	293	295	6.13e-06	45.8
k141_68134_66	CARD|gb|BAB41874.1|ARO:3000815|mgrA	31.4	118	143	147	8.58e-10	52.8
k141_70180_3	CARD|gb|CAA79966.1|ARO:3003665|NmcR	28.4	313	304	295	1.83e-09	56.6
k141_70180_29	NCBI|AJP12342.1|1|1|cplR|cplR|target_protection|1|CLINDAMYCIN/LINCOMYCIN/RETAPAMULIN/VIRGINIAMYCIN|LINCOSAMIDE/PLEUROMUTILIN/STREPTOGRAMIN|ABC-F_type_ribosomal_protection_protein_CplR|AMR|multidrug	35.0	100	229	550	1.22e-12	65.5
k141_70180_29	CARD|gb|BAB80490.1|ARO:3007644|Cper_cplR	38.5	78	229	568	2.02e-10	58.9
k141_70180_29	NCBI|WP_032492560.1|1|1|vga(A)|vga(A)|target_protection|2|LINCOSAMIDE|LINCOSAMIDE|ABC-F_type_ribosomal_protection_protein_Vga(A)|AMR|lincosamide	32.7	98	229	522	1.71e-08	53.1
k141_70180_29	SARG|DQ823382.1.gene1.p01	32.7	98	229	522	1.71e-08	53.1
k141_70180_29	megares|MEG_7687|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|VGA_1	32.7	98	229	522	1.71e-08	53.1
k141_70180_29	megares|MEG_7686|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|VGA_1	32.7	98	229	522	1.71e-08	53.1
k141_70180_29	SARG|AAF24091	32.7	98	229	522	1.71e-08	53.1
k141_70180_29	SARG|YP_002332257	32.7	98	229	522	1.71e-08	53.1
k141_70180_29	SARG|gb|CBL58195.1|ARO:3002831|vgaC	35.2	88	229	522	2.29e-08	52.8
k141_70180_29	SARG|AAG08983	36.4	88	229	524	3.09e-08	52.4
k141_70180_53	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	41.8	225	229	232	6.65e-59	184
k141_70180_53	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	41.8	225	229	232	6.65e-59	184
k141_70180_53	NCBI|WP_034872470.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	41.3	225	229	231	2.59e-58	183
k141_70180_53	NCBI|WP_003126775.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	41.3	225	229	231	1.47e-57	181
k141_70180_53	NCBI|WP_063856725.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	40.9	225	229	231	1.47e-57	181
k141_70180_53	NCBI|WP_063856724.1|1|1|vanR-L|vanR-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-L|AMR|glycopeptide	39.7	224	229	231	4.18e-57	180
k141_70180_53	NCBI|WP_005228837.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	40.4	225	229	231	2.37e-56	178
k141_70180_53	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	41.2	226	229	231	3.36e-56	177
k141_70180_53	NCBI|WP_063856728.1|1|1|vanR-N|vanR-N|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-N|AMR|glycopeptide	41.9	227	229	230	4.61e-56	177
k141_70180_53	NCBI|WP_222891057.1|1|1|vanR-P|vanR-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-P|AMR|glycopeptide	42.7	234	229	239	6.03e-56	177
k141_70180_54	NCBI|WP_222891058.1|1|1|vanS-P|vanS-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-P|AMR|glycopeptide	25.0	264	494	359	1.80e-21	94.7
k141_70180_56	SARG|gi|441475675|emb|CCQ25429.1|	31.3	134	446	211	2.08e-10	59.3
k141_70180_56	SARG|HE999704.1.gene3064.p01	31.3	134	446	241	3.06e-10	59.3
k141_70180_66	NCBI|AAN33534.1|1|1|bepG|bepG|efflux|1|EFFLUX|EFFLUX|multidrug_efflux_RND_transporter_permease_subunit_BepG|AMR|efflux	42.5	1050	1051	1074	4.08e-267	778
k141_70180_66	CARD|gb|ABS43151.1|ARO:3000784|cmeB	42.0	1040	1051	1040	3.14e-263	766
k141_70180_66	NCBI|AAN29241.1|1|1|bepE|bepE|efflux|1|EFFLUX|EFFLUX|multidrug_efflux_RND_transporter_permease_subunit_BepE|AMR|efflux	42.8	1040	1051	1051	5.60e-258	753
k141_70180_66	SARG|EEB58431	40.8	1060	1051	1063	1.15e-254	745
k141_70180_66	SARG|NP_792892	40.8	1060	1051	1063	2.29e-254	744
k141_70180_66	SARG|gi|491017944|ref|WP_004879650.1|	41.2	1046	1051	1063	3.23e-254	744
k141_70180_66	SARG|gi|940417834|ref|WP_055007142.1|	40.9	1060	1051	1063	2.56e-253	742
k141_70180_66	SARG|YP_236040	41.5	1046	1051	1063	3.62e-253	741
k141_70180_66	SARG|gi|489273629|ref|WP_003181339.1|	41.4	1045	1051	1059	4.51e-253	741
k141_70180_66	SARG|YP_001348104	41.9	1047	1051	1062	6.99e-253	741
k141_70180_67	NCBI|WP_063865373.1|1|1|oqxA5|oqxA|efflux|2|PHENICOL/quinolone|PHENICOL/quinolone|multidrug_efflux_RND_transporter_periplasmic_adaptor_subunit_OqxA5|AMR|multidrug	34.7	349	391	391	5.36e-49	169
k141_70180_67	NCBI|WP_063865368.1|1|1|oqxA4|oqxA|efflux|2|PHENICOL/quinolone|PHENICOL/quinolone|multidrug_efflux_RND_transporter_periplasmic_adaptor_subunit_OqxA4|AMR|multidrug	34.4	349	391	391	1.47e-48	168
k141_70180_67	NCBI|WP_063865390.1|1|1|oqxA8|oqxA|efflux|2|PHENICOL/quinolone|PHENICOL/quinolone|multidrug_efflux_RND_transporter_periplasmic_adaptor_subunit_OqxA8|AMR|multidrug	34.4	349	391	391	1.47e-48	168
k141_70180_67	NCBI|WP_063865358.1|1|1|oqxA2|oqxA|efflux|2|PHENICOL/quinolone|PHENICOL/quinolone|multidrug_efflux_RND_transporter_periplasmic_adaptor_subunit_OqxA2|AMR|multidrug	34.7	349	391	391	2.05e-48	167
k141_70180_67	NCBI|WP_004890321.1|1|1|oqxA3|oqxA|efflux|2|PHENICOL/quinolone|PHENICOL/quinolone|multidrug_efflux_RND_transporter_periplasmic_adaptor_subunit_OqxA3|AMR|multidrug	34.4	349	391	391	2.05e-48	167
k141_70180_67	SARG|gb|AAP43109.1|ARO:3003922|oqxA	34.4	349	391	391	2.87e-48	167
k141_70180_67	NCBI|WP_004212918.1|1|1|oqxA11|oqxA|efflux|2|PHENICOL/quinolone|PHENICOL/quinolone|multidrug_efflux_RND_transporter_periplasmic_adaptor_subunit_OqxA11|AMR|multidrug	34.4	349	391	391	2.87e-48	167
k141_70180_67	NCBI|WP_063865399.1|1|1|oqxA9|oqxA|efflux|2|PHENICOL/quinolone|PHENICOL/quinolone|multidrug_efflux_RND_transporter_periplasmic_adaptor_subunit_OqxA9|AMR|multidrug	34.4	349	391	391	2.87e-48	167
k141_70180_67	NCBI|WP_047693838.1|1|1|oqxA6|oqxA|efflux|2|PHENICOL/quinolone|PHENICOL/quinolone|multidrug_efflux_RND_transporter_periplasmic_adaptor_subunit_OqxA6|AMR|multidrug	34.1	349	391	391	7.84e-48	166
k141_70180_67	SARG|NC_009085.4918693.p01	34.8	313	391	376	1.09e-47	165
k141_70180_82	megares|MEG_4090|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	20.6	832	827	1024	1.89e-27	118
k141_70180_82	SARG|gb|CAA53189|ARO:3000521|mupA	20.6	832	827	1024	1.89e-27	118
k141_70180_82	NCBI|WP_000163435.1|1|1|mupA|mupA|insensitivity|2|mupirocin|mupirocin|mupirocin-resistant_isoleucine--tRNA_ligase_MupA|AMR|mupirocin	20.4	832	827	1024	5.72e-27	117
k141_70180_82	megares|MEG_4089|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	20.4	832	827	1024	5.72e-27	117
k141_70180_82	megares|MEG_3295|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|ILES_1	21.9	892	827	1107	4.44e-14	75.5
k141_70180_82	SARG|gb|ADP36409.1|ARO:3003730|Bifidobacteria	21.9	892	827	1107	4.44e-14	75.5
k141_70180_128	SARG|gb|AAC75314.1|ARO:3003578|pmrF	31.0	306	309	322	3.46e-44	152
k141_70180_149	SARG|gb|ABX54687.1|ARO:3002910|vanL	31.2	340	313	349	1.14e-41	146
k141_70180_149	NCBI|WP_063856657.1|1|1|vanC2/3|vanC2/3|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-alanine--D-serine_ligase_VanC2/3|AMR|glycopeptide	30.6	346	313	350	8.74e-41	144
k141_70180_149	NCBI|WP_063856666.1|1|1|vanC2/3|vanC2/3|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-alanine--D-serine_ligase_VanC2/3|AMR|glycopeptide	30.1	346	313	350	3.35e-40	142
k141_70180_149	SARG|DQ212986.1.gene8.p01	34.7	248	313	349	2.46e-39	140
k141_70180_149	SARG|gi|405945042|pdb|4FU0|A	34.7	248	313	357	2.90e-39	140
k141_70180_149	SARG|gi|752682279|ref|WP_041330231.1|	34.3	248	313	349	4.80e-39	139
k141_70180_149	SARG|gi|765411304|ref|WP_044689514.1|	34.7	248	313	349	4.80e-39	139
k141_70180_149	SARG|gi|1028100561|ref|WP_063856696.1|	33.5	248	313	349	6.71e-39	139
k141_70180_149	NCBI|WP_063856652.1|1|1|vanC2/3|vanC2/3|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-alanine--D-serine_ligase_VanC2/3|AMR|glycopeptide	29.5	349	313	350	6.85e-39	139
k141_70180_149	SARG|AAF71281	34.3	248	313	349	1.31e-38	138
k141_70180_154	megares|MEG_7571|Drugs|Glycopeptide|VanM-type_resistance_protein|VANXM_2	38.1	451	457	451	3.16e-93	288
k141_70180_154	megares|MEG_7572|Drugs|Glycopeptide|VanM-type_resistance_protein|VANXM_2	37.9	451	457	481	4.17e-92	286
k141_70180_154	megares|MEG_7563|Drugs|Glycopeptide|VanB-type_resistance_protein|VANXB_2	37.2	449	457	451	7.00e-92	285
k141_70180_172	NCBI|WP_063856732.1|1|1|vanS-G|vanS-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-G|AMR|glycopeptide	27.0	237	517	367	3.37e-23	100
k141_70180_172	NCBI|WP_021418927.1|1|1|vanS-G|vanS-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-G|AMR|glycopeptide	27.0	237	517	368	3.41e-23	100
k141_70180_172	megares|MEG_7521|Drugs|Glycopeptide|VanN-type_regulator|VANSN_1	24.6	232	517	364	1.30e-20	92.4
k141_70180_172	NCBI|WP_063856749.1|1|1|vanS-N|vanS-N|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-N|AMR|glycopeptide	24.6	232	517	364	1.30e-20	92.4
k141_70180_172	NCBI|AXB64455.1|1|1|vanS-Cd|vanS-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|VanG-Cd-type_glycopeptide_resistance_histidine_kinase_VanS|AMR|glycopeptide	25.2	222	517	380	2.78e-20	91.7
k141_70180_172	megares|MEG_7498|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	25.2	222	517	380	2.78e-20	91.7
k141_70180_172	megares|MEG_7501|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	26.2	237	517	354	5.14e-20	90.5
k141_70180_172	megares|MEG_7514|Drugs|Glycopeptide|VanL-type_regulator|VANSL_1	25.0	228	517	364	1.88e-19	89.0
k141_70180_172	NCBI|WP_063856745.1|1|1|vanS-L|vanS-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-L|AMR|glycopeptide	25.0	228	517	364	1.88e-19	89.0
k141_70180_172	megares|MEG_7503|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	25.7	237	517	354	2.27e-19	88.6
k141_70180_173	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	42.3	227	222	232	2.71e-56	177
k141_70180_173	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	42.3	227	222	232	2.71e-56	177
k141_70180_173	NCBI|WP_063856728.1|1|1|vanR-N|vanR-N|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-N|AMR|glycopeptide	40.7	226	222	230	2.65e-53	170
k141_70180_173	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	41.2	228	222	232	6.38e-52	166
k141_70180_173	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	40.9	225	222	229	1.17e-51	166
k141_70180_173	CARD|gb|AAD51348.1|ARO:3003066|smeR	40.0	220	222	229	2.34e-51	165
k141_70180_173	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	39.2	227	222	231	4.96e-51	164
k141_70180_173	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	39.2	227	222	231	4.96e-51	164
k141_70180_173	NCBI|WP_001280781.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	38.6	228	222	231	7.02e-51	164
k141_70180_173	NCBI|WP_005228837.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	40.0	225	222	231	7.02e-51	164
k141_70180_226	megares|MEG_6058|Drugs|MLS|23S_rRNA_methyltransferases|RLMH_1	41.1	158	160	159	1.33e-39	130
k141_70180_228	NCBI|WP_256875606.1|1|1|blaNWM-1|blaNWM|hydrolase|2|CARBAPENEM|beta-lactam|subclass_B3_metallo-beta-lactamase_NWM-1|AMR|beta-lactam	31.7	123	313	310	2.30e-06	47.4
k141_45257_32	NCBI|WP_222891057.1|1|1|vanR-P|vanR-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-P|AMR|glycopeptide	44.4	234	233	239	3.33e-59	186
k141_45257_32	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	43.4	228	233	228	3.38e-59	185
k141_45257_32	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	42.4	231	233	233	6.33e-58	182
k141_45257_32	NCBI|WP_005228837.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	42.3	227	233	231	8.44e-58	182
k141_45257_32	NCBI|WP_063856725.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	42.3	227	233	231	2.39e-57	181
k141_45257_32	NCBI|WP_034872470.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	42.3	227	233	231	3.39e-57	180
k141_45257_32	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	43.7	229	233	231	4.79e-57	180
k141_45257_32	NCBI|WP_003126775.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	41.4	227	233	231	1.36e-56	179
k141_45257_32	NCBI|WP_063856724.1|1|1|vanR-L|vanR-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-L|AMR|glycopeptide	42.5	226	233	231	2.72e-56	178
k141_45257_32	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	40.9	232	233	229	4.12e-55	175
k141_93676_10	SARG|NP_934523	29.7	428	454	456	1.09e-55	190
k141_93676_10	SARG|Q8D9N8	29.4	428	454	456	5.78e-55	188
k141_93676_10	NCBI|AAC23256.1|1|1|hmrM|hmrM|efflux|1|EFFLUX|EFFLUX|sodium-coupled_multidrug_efflux_MATE_transporter_HmrM|AMR|efflux	28.6	430	454	464	2.68e-53	184
k141_93676_10	SARG|gb|ADO96486.1|ARO:3003953|hmrM	28.6	430	454	464	5.21e-53	183
k141_93676_10	SARG|gi|489863287|ref|WP_003766901.1|	27.9	433	454	459	1.89e-46	166
k141_93676_10	SARG|gi|488156254|ref|WP_002227462.1|	28.2	433	454	459	9.74e-46	164
k141_93676_10	SARG|gi|488158065|ref|WP_002229273.1|	28.2	433	454	459	1.88e-45	163
k141_93676_10	SARG|gb|AAG04750.1|ARO:3004077|PmpM	29.3	443	454	477	3.60e-45	162
k141_93676_11	megares|MEG_727|Drugs|beta-lactam|Class_C_betalactamases|AMPC_1	39.2	408	411	415	3.89e-102	308
k141_93676_12	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	41.8	220	348	255	1.73e-52	173
k141_93676_12	SARG|gi|736472622|ref|WP_034494292.1|	34.9	252	348	648	5.74e-41	150
k141_93676_12	SARG|gi|1035706844|ref|WP_064548272.1|	35.7	235	348	648	5.74e-41	150
k141_93676_12	SARG|gi|803568669|ref|WP_046077412.1|	38.2	220	348	648	1.49e-40	149
k141_93676_12	SARG|gi|446110352|ref|WP_000188207.1|	38.2	220	348	648	1.49e-40	149
k141_93676_12	SARG|YP_002382193	38.2	220	348	648	1.49e-40	149
k141_93676_12	SARG|gi|803575554|ref|WP_046081557.1|	38.2	220	348	648	1.49e-40	149
k141_93676_12	SARG|gi|446110351|ref|WP_000188206.1|	38.2	220	348	648	1.49e-40	149
k141_93676_12	SARG|gi|1035670474|ref|WP_064517458.1|	32.9	252	348	648	2.80e-40	149
k141_93676_12	SARG|gi|1035717981|ref|WP_064557480.1|	35.3	235	348	648	2.80e-40	149
k141_75689_47	SARG|ZP_03225116	46.8	269	276	263	1.38e-80	243
k141_75689_47	SARG|ZP_04310898	48.4	275	276	263	3.18e-79	239
k141_75689_47	SARG|NP_977823	48.0	275	276	263	6.37e-79	238
k141_75689_47	SARG|ZP_04144736	48.0	275	276	263	9.03e-79	238
k141_75689_47	SARG|ZP_04288431	48.0	275	276	263	1.28e-78	238
k141_75689_47	SARG|ZP_04299687	48.0	275	276	263	1.28e-78	238
k141_75689_47	SARG|ZP_04202328	47.6	275	276	263	1.28e-78	238
k141_75689_47	SARG|ZP_04150458	48.4	275	276	264	1.32e-78	238
k141_75689_47	SARG|NP_843860	47.6	275	276	263	2.57e-78	237
k141_75689_47	SARG|Q6HLG8	47.6	275	276	263	2.57e-78	237
k141_75689_52	SARG|gi|949731360|ref|WP_057072003.1|	38.8	227	280	646	6.54e-35	131
k141_75689_52	SARG|gi|998245120|ref|WP_061098715.1|	38.1	231	280	646	3.13e-34	129
k141_75689_52	SARG|gi|695731723|ref|WP_032658224.1|	38.2	228	280	646	5.84e-34	129
k141_75689_52	SARG|gi|829911593|ref|WP_047362788.1|	38.2	228	280	646	5.84e-34	129
k141_75689_52	SARG|gi|1016942913|ref|WP_063144441.1|	38.2	228	280	646	5.84e-34	129
k141_75689_52	SARG|gi|835749851|ref|WP_047648187.1|	38.2	228	280	646	5.84e-34	129
k141_75689_52	SARG|gi|697052471|ref|WP_033145077.1|	38.2	228	280	646	5.84e-34	129
k141_75689_52	SARG|gi|779861244|ref|WP_045352062.1|	38.6	228	280	646	5.84e-34	129
k141_75689_52	SARG|gi|779958642|ref|WP_045406003.1|	38.1	231	280	646	5.84e-34	129
k141_75689_52	SARG|gi|695722592|ref|WP_032649220.1|	38.2	228	280	646	5.84e-34	129
k141_75689_53	SARG|gb|AAA26793|ARO:3003748|oleC	34.0	212	291	325	1.18e-27	108
k141_75689_53	megares|MEG_4276|Drugs|MLS|MLS_resistance_ABC_efflux_pumps|OLEC_1	34.0	212	291	325	1.18e-27	108
k141_75689_53	SARG|gb|APB03214.1|ARO:3003980|tetA(48)	29.4	218	291	343	1.45e-24	100
k141_75689_53	SARG|gb|AYV52072.1|ARO:3002882|lmrD	29.0	238	291	664	5.80e-24	100
k141_75689_53	SARG|gb|AET10445.1|ARO:3004033|tetB(46)	29.5	237	291	578	1.65e-21	93.2
k141_75689_53	NCBI|WP_289811733.1|1|1|tetB(60)|tetB(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_B|AMR|tetracycline	30.8	250	291	579	1.51e-19	87.4
k141_75689_53	SARG|gb|WP_104671188.1|ARO:3003948|efrA	28.8	236	291	575	2.03e-19	87.0
k141_75689_53	SARG|gb|ANZ79241.1|ARO:3004036|tetB(60)	30.8	250	291	579	2.04e-19	87.0
k141_75689_53	SARG|gb|AAK76136.1|ARO:3000025|patB	27.3	231	291	588	1.36e-17	81.6
k141_75689_53	NCBI|QHA94808.1|1|1|narA|narA||1|MADURAMICIN/NARASIN/SALINOMYCIN|IONOPHORE|ionophore_ABC_transporter_ATP-binding_subunit_NarA|AMR|ionophore	24.8	226	291	293	1.37e-15	74.3
k141_75689_64	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	38.5	218	228	219	2.80e-43	144
k141_75689_64	NCBI|WP_063856719.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	38.5	218	228	220	2.88e-43	144
k141_75689_64	NCBI|WP_032489743.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	38.5	218	228	220	4.06e-43	144
k141_75689_64	NCBI|WP_063856723.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	38.1	218	228	219	2.22e-42	142
k141_75689_64	NCBI|WP_002368697.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	38.5	218	228	220	2.28e-42	142
k141_75689_64	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	36.2	229	228	231	1.73e-41	140
k141_75689_64	SARG|ZP_02848503	37.2	218	228	221	1.64e-39	134
k141_75689_64	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	34.8	230	228	232	4.37e-39	134
k141_75689_65	NCBI|WP_063856748.1|1|1|vanS-M|vanS-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-M|AMR|glycopeptide	30.8	211	567	370	2.91e-27	112
k141_75689_65	CARD|gb|ABD30512.1|ARO:3000839|arlS	27.6	217	567	451	1.10e-26	112
k141_75689_65	megares|MEG_7514|Drugs|Glycopeptide|VanL-type_regulator|VANSL_1	30.1	219	567	364	1.02e-25	107
k141_75689_65	NCBI|WP_063856745.1|1|1|vanS-L|vanS-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-L|AMR|glycopeptide	30.1	219	567	364	1.02e-25	107
k141_75689_65	NCBI|WP_006285582.1|1|1|vanS-F|vanS-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-F|AMR|glycopeptide	28.4	225	567	365	6.31e-25	105
k141_75689_65	NCBI|WP_021418927.1|1|1|vanS-G|vanS-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-G|AMR|glycopeptide	31.3	217	567	368	9.83e-24	102
k141_75689_65	NCBI|WP_063856732.1|1|1|vanS-G|vanS-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-G|AMR|glycopeptide	31.6	215	567	367	1.31e-23	101
k141_75689_65	NCBI|WP_028530133.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	30.0	233	567	381	1.57e-23	101
k141_75689_65	NCBI|WP_023042297.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	29.3	232	567	381	1.57e-23	101
k141_75689_65	megares|MEG_7506|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	30.0	233	567	381	1.57e-23	101
k141_75689_86	SARG|gi|860594225|ref|WP_048475168.1|	39.2	567	589	620	3.11e-130	394
k141_75689_86	SARG|gi|926351744|ref|WP_053683383.1|	39.2	567	589	648	2.18e-128	390
k141_75689_86	SARG|gi|944009777|ref|WP_055601444.1|	38.4	578	589	628	6.85e-128	388
k141_75689_86	SARG|gi|517347347|ref|WP_018522839.1|	38.6	567	589	601	8.72e-128	387
k141_75689_86	SARG|gi|664556405|ref|WP_031071225.1|	38.9	576	589	602	8.99e-128	387
k141_75689_86	SARG|gi|695842130|ref|WP_032755430.1|	38.3	567	589	603	2.60e-127	385
k141_75689_86	SARG|gi|919568551|ref|WP_052871170.1|	38.4	567	589	620	3.03e-127	386
k141_75689_86	SARG|gi|917229923|ref|WP_051836635.1|	38.8	567	589	620	3.03e-127	386
k141_75689_86	SARG|gi|921231571|ref|WP_053176464.1|	38.3	567	589	620	3.03e-127	386
k141_75689_86	SARG|gi|516795764|ref|WP_018105258.1|	38.6	567	589	601	3.46e-127	385
k141_75689_96	SARG|gi|447195835|ref|WP_001273091.1|	36.3	215	240	306	3.60e-34	123
k141_75689_96	SARG|gi|447195836|ref|WP_001273092.1|	36.3	215	240	306	5.05e-34	123
k141_75689_96	SARG|gi|500448961|gb|EOP61695.1|	35.3	218	240	306	7.07e-34	122
k141_75689_96	SARG|gi|500465078|gb|EOP76697.1|	35.3	218	240	306	1.39e-33	122
k141_75689_96	SARG|ZP_04081918	35.8	215	240	306	1.95e-33	121
k141_75689_96	SARG|gi|507044560|ref|WP_016115614.1|	36.1	219	240	306	7.48e-33	120
k141_75689_96	SARG|YP_001373621	34.1	217	240	318	3.64e-32	118
k141_75689_115	SARG|gb|BAG33043.1|ARO:3003920|pgpB	26.0	192	181	236	3.49e-11	58.9
k141_75689_115	megares|MEG_5776|Drugs|Lipopeptide|Lipid_A_phosphatase|PGBB_1	25.5	192	181	236	9.08e-11	57.8
k141_75689_119	SARG|gb|APB03219.1|ARO:3003986|TaeA	32.2	659	643	648	5.33e-101	320
k141_75689_119	megares|MEG_4308|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	35.9	521	643	655	1.02e-98	315
k141_75689_119	megares|MEG_4318|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	35.9	521	643	655	2.00e-98	314
k141_75689_119	megares|MEG_4309|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	35.9	521	643	655	7.74e-98	312
k141_75689_119	megares|MEG_4316|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	35.7	521	643	655	1.09e-97	312
k141_75689_119	megares|MEG_4307|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	35.7	521	643	655	1.52e-97	311
k141_75689_119	megares|MEG_4304|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	35.7	521	643	655	1.52e-97	311
k141_75689_119	SARG|gb|AKA86814|ARO:3003746|optrA	35.7	521	643	655	1.52e-97	311
k141_75689_119	megares|MEG_4322|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	35.7	521	643	655	2.13e-97	311
k141_75689_119	megares|MEG_4313|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	35.7	521	643	655	2.99e-97	311
k141_75689_125	SARG|gb|AAV85982.1|ARO:3000535|macB	37.2	401	406	644	2.88e-69	229
k141_75689_125	SARG|gi|639209604|ref|WP_024547784.1|	38.0	411	406	648	6.67e-66	220
k141_75689_125	SARG|gi|836589868|ref|WP_047747112.1|	38.7	408	406	646	1.25e-65	219
k141_75689_125	SARG|gi|647640371|ref|WP_025912926.1|	38.5	408	406	646	4.74e-65	218
k141_75689_125	SARG|gi|765031087|ref|WP_044596899.1|	38.5	408	406	646	4.74e-65	218
k141_75689_125	SARG|gi|556495988|ref|WP_023343675.1|	38.5	408	406	646	4.74e-65	218
k141_75689_125	SARG|gi|556301718|ref|WP_023292894.1|	38.5	408	406	646	4.74e-65	218
k141_75689_125	SARG|gi|495775415|ref|WP_008499994.1|	38.5	408	406	646	4.74e-65	218
k141_75689_125	SARG|gi|1022680162|ref|WP_063435808.1|	38.5	408	406	646	4.74e-65	218
k141_75689_125	SARG|gi|896083144|ref|WP_049122651.1|	38.5	408	406	646	4.74e-65	218
k141_75689_126	SARG|gb|AAV85982.1|ARO:3000535|macB	53.6	224	235	644	7.18e-72	229
k141_75689_126	SARG|gi|695793471|ref|WP_032707680.1|	50.9	224	235	648	1.08e-71	229
k141_75689_126	SARG|gi|823302270|ref|WP_047057473.1|	50.9	224	235	648	1.52e-71	229
k141_75689_126	SARG|gi|976146774|ref|WP_059305359.1|	50.9	224	235	648	1.52e-71	229
k141_75689_126	SARG|gi|1022664304|ref|WP_063420886.1|	50.9	224	235	648	1.52e-71	229
k141_75689_126	SARG|gi|823309640|ref|WP_047064288.1|	50.9	224	235	648	1.52e-71	229
k141_75689_126	SARG|gi|505807117|ref|WP_015704872.1|	50.9	224	235	648	1.52e-71	229
k141_75689_126	SARG|gi|518923394|ref|WP_020079269.1|	50.9	224	235	648	1.52e-71	229
k141_75689_126	SARG|gi|695797094|ref|WP_032711285.1|	50.9	224	235	648	1.52e-71	229
k141_75689_126	SARG|gi|823299155|ref|WP_047054544.1|	50.9	224	235	648	1.52e-71	229
k141_75689_131	NCBI|WP_087347987.1|1|1|rphC|rphC||2|rifamycin|rifamycin|rifamycin-inactivating_phosphotransferase_RphC|AMR|rifamycin	40.2	321	803	868	7.61e-65	231
k141_75689_131	NCBI|WP_087348261.1|1|1|rphD|rphD||2|rifamycin|rifamycin|rifamycin-inactivating_phosphotransferase_RphD|AMR|rifamycin	39.7	320	803	872	7.96e-65	231
k141_75689_131	SARG|gb|APB03222.1|ARO:3003992|rphB	39.8	324	803	884	3.14e-64	230
k141_75689_131	SARG|gb|AIA08936.1|ARO:3000444|rphA	38.6	321	803	865	3.80e-55	203
k141_75689_152	CARD|gb|ABV18113.1|ARO:3001329|mdtG	32.4	386	398	408	1.80e-60	200
k141_75689_152	SARG|gi|815842605|ref|WP_046464285.1|	24.5	355	398	388	1.34e-16	79.7
k141_75689_152	SARG|gi|970426279|ref|WP_058710176.1|	24.2	355	398	388	4.35e-16	78.2
k141_75689_152	SARG|ZP_04677690	23.2	393	398	388	1.05e-15	77.0
k141_75689_152	SARG|gi|896520548|ref|WP_049425590.1|	24.2	355	398	388	1.41e-15	76.6
k141_75689_152	SARG|gi|556618713|ref|WP_023374778.1|	24.2	355	398	388	1.89e-15	76.3
k141_75689_152	SARG|gi|656016562|ref|WP_029056449.1|	22.8	390	398	386	3.50e-14	72.4
k141_75689_152	SARG|gi|516233382|ref|WP_017637345.1|	22.8	390	398	386	4.68e-14	72.0
k141_75689_152	SARG|gi|950716651|ref|WP_057492920.1|	21.8	395	398	387	1.53e-12	67.4
k141_75689_152	SARG|gi|983367678|ref|WP_060546533.1|	21.8	395	398	387	2.04e-12	67.0
k141_75689_155	SARG|gi|742378414|ref|WP_038857601.1|	36.6	235	331	647	1.58e-24	103
k141_75689_155	SARG|gi|506220920|ref|WP_015740695.1|	36.2	235	331	647	2.87e-24	102
k141_75689_155	SARG|gi|504542119|ref|WP_014729221.1|	36.2	235	331	647	3.88e-24	102
k141_75689_155	SARG|gi|565651791|ref|WP_023899061.1|	35.7	235	331	647	3.88e-24	102
k141_75689_155	SARG|gi|851922185|ref|WP_048218206.1|	36.2	235	331	648	3.88e-24	102
k141_75689_155	SARG|gi|949718947|ref|WP_057063453.1|	36.2	235	331	648	3.88e-24	102
k141_75689_155	SARG|gi|696375069|ref|WP_032949617.1|	36.2	235	331	648	3.88e-24	102
k141_75689_155	SARG|gi|489127020|ref|WP_003036815.1|	36.2	235	331	648	3.88e-24	102
k141_75689_155	SARG|YP_001438541	36.2	235	331	647	7.07e-24	101
k141_75689_155	SARG|gi|938461734|ref|WP_054625806.1|	36.2	235	331	647	7.07e-24	101
k141_75689_156	SARG|gi|500448961|gb|EOP61695.1|	31.4	207	323	306	1.49e-23	97.4
k141_75689_156	SARG|gi|500465078|gb|EOP76697.1|	31.9	207	323	306	1.49e-23	97.4
k141_75689_156	SARG|gi|447195835|ref|WP_001273091.1|	30.9	207	323	306	1.94e-22	94.4
k141_75689_156	SARG|gi|447195836|ref|WP_001273092.1|	30.4	207	323	306	5.07e-22	93.2
k141_75689_156	SARG|ZP_04081918	30.0	207	323	306	2.50e-21	91.3
k141_75689_156	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	28.8	222	323	255	2.89e-21	90.1
k141_75689_156	SARG|gi|500194536|ref|WP_011867743.1|	30.0	207	323	306	3.16e-20	88.2
k141_75689_156	SARG|gb|AET10444.1|ARO:3004032|tetA(46)	26.8	220	323	574	1.18e-12	67.4
k141_84709_51	SARG|gi|446573707|ref|WP_000651053.1|	23.6	415	451	451	3.21e-30	120
k141_84709_51	SARG|gi|686432388|ref|WP_031921070.1|	23.6	415	451	451	1.11e-29	119
k141_84709_51	SARG|gi|446573718|ref|WP_000651064.1|	22.9	415	451	451	1.11e-29	119
k141_84709_51	SARG|gi|446573700|ref|WP_000651046.1|	23.4	415	451	451	1.11e-29	119
k141_84709_51	SARG|ZP_03986195	23.4	415	451	451	1.52e-29	119
k141_84709_51	SARG|gi|446573695|ref|WP_000651041.1|	23.4	415	451	451	1.52e-29	119
k141_84709_51	SARG|gi|505177635|ref|WP_015364737.1|	23.8	445	451	451	1.52e-29	119
k141_84709_51	SARG|gi|565830932|ref|WP_023914633.1|	23.1	415	451	451	2.82e-29	118
k141_84709_51	SARG|gi|686155635|ref|WP_031787393.1|	22.7	415	451	451	2.82e-29	118
k141_84709_51	SARG|gi|686355454|ref|WP_031890196.1|	23.9	418	451	451	2.82e-29	118
k141_84709_54	SARG|ZP_02952732	28.5	456	535	652	2.97e-40	153
k141_84709_54	SARG|L20800.gene.p01	28.3	456	535	652	2.97e-40	153
k141_84709_54	SARG|ZP_02632674	28.5	456	535	660	3.17e-40	153
k141_84709_54	SARG|YP_002850805	28.5	456	535	652	4.04e-40	153
k141_84709_54	SARG|NP_348076	28.1	456	535	652	1.59e-38	148
k141_84709_54	SARG|CAA37477	27.8	464	535	663	5.28e-33	132
k141_84709_54	NCBI|WP_063856408.1|1|1|tet(Q)|tet(Q)|target_protection|2|TETRACYCLINE|TETRACYCLINE|tetracycline_resistance_ribosomal_protection_protein_Tet(Q)|AMR|tetracycline	25.7	452	535	654	9.82e-32	128
k141_84709_54	megares|MEG_7182|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETQ_1	25.7	452	535	670	1.05e-31	128
k141_84709_54	SARG|AAB51122	25.7	452	535	670	1.05e-31	128
k141_84709_54	SARG|Q08425	25.7	452	535	641	1.68e-31	127
k141_33825_8	SARG|gb|AAG07065.1|ARO:3003692|mexJ	32.9	353	364	367	6.62e-47	162
k141_33825_8	CARD|gb|AAG03547.1|ARO:3003680|TriB	33.0	345	364	356	1.88e-39	142
k141_33825_9	SARG|gb|AAG07064.1|ARO:3003693|mexK	43.6	1020	1015	1025	1.32e-285	822
k141_33825_9	CARD|gb|AAG03548.1|ARO:3003681|TriC	41.2	1015	1015	1015	1.94e-265	770
k141_33825_9	SARG|YP_001670703	23.9	1021	1015	1014	1.05e-62	230
k141_33825_9	SARG|YP_350221	23.9	1041	1015	1009	2.45e-62	229
k141_33825_9	SARG|YP_001266290	24.1	1018	1015	1014	1.10e-61	227
k141_33825_9	SARG|CAY51926	24.3	1037	1015	1008	1.10e-60	224
k141_33825_9	SARG|YP_001186705	24.2	1036	1015	1017	1.57e-60	223
k141_33825_9	SARG|YP_001348104	24.2	1071	1015	1062	6.56e-59	219
k141_33825_9	SARG|gi|950592507|ref|WP_057454502.1|	23.8	1061	1015	1063	6.59e-59	219
k141_33825_9	SARG|YP_348389	23.7	1062	1015	1063	6.59e-59	219
k141_43647_4	SARG|gb|CCP45647.1|ARO:3003955|efpA	24.5	212	401	530	5.94e-08	53.5
k141_43647_8	ResF|penA_1_AF515059_1	29.2	565	665	581	6.62e-70	237
k141_43647_8	SARG|gb|AQX82857.1|ARO:3004185|mecD	25.8	542	665	678	4.90e-25	109
k141_43647_8	NCBI|WP_063852710.1|1|1|mecB|mecB|insensitivity|2|METHICILLIN|beta-lactam|PBP2a_family_beta-lactam-resistant_peptidoglycan_transpeptidase_MecB|AMR|beta-lactam	24.1	511	665	674	4.15e-22	100
k141_43647_8	SARG|gi|2791908|emb|CAA73538.1|	24.7	543	665	666	2.90e-21	97.4
k141_43647_8	megares|MEG_3792|Drugs|beta-lactam|Penicillin_binding_protein|MECA_1	24.7	543	665	666	3.84e-21	97.1
k141_43647_8	NCBI|WP_128268231.1|1|1|mecC2|mecC2|insensitivity|2|METHICILLIN|beta-lactam|PBP2a_family_beta-lactam-resistant_peptidoglycan_transpeptidase_MecC2|AMR|beta-lactam	25.1	546	665	665	6.71e-21	96.3
k141_43647_8	NCBI|WP_069996660.1|1|1|mecC3|mecC3|insensitivity|2|METHICILLIN|beta-lactam|PBP2a_family_beta-lactam-resistant_peptidoglycan_transpeptidase_MecC3|AMR|beta-lactam	24.4	544	665	665	1.79e-18	88.6
k141_43647_8	SARG|gb|CCC86795.1|ARO:3001209|mecC	24.7	546	665	665	1.79e-18	88.6
k141_43647_8	megares|MEG_3799|Drugs|beta-lactam|Penicillin_binding_protein|MECC_1	24.5	546	665	664	4.13e-18	87.4
k141_43647_8	NCBI|WP_049151672.1|1|1|pbp2m|pbp2m||2|beta-lactam|beta-lactam|penicillin-binding_protein_PBP2M|AMR|beta-lactam	27.4	303	665	593	3.35e-17	84.3
k141_87198_4	SARG|YP_002333394	36.4	231	316	323	2.60e-34	126
k141_87198_4	SARG|AF310956.2.gene5.p01	35.9	231	316	323	9.83e-34	125
k141_87198_4	NCBI|WP_063856701.1|1|1|vanH-B|vanH-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-B|AMR|glycopeptide	35.9	231	316	323	9.83e-34	125
k141_87198_4	SARG|Q47748	35.1	231	316	323	1.01e-32	122
k141_87198_4	SARG|gb|AAB05626.1|ARO:3002943|vanHB	35.1	231	316	323	1.01e-32	122
k141_87198_4	SARG|AAF72362	35.5	231	316	323	1.40e-32	122
k141_87198_4	SARG|gb|MBY8651254.1|ARO:3007188|vanH_in_vanP_cl	31.9	232	316	314	1.63e-32	121
k141_87198_4	SARG|gi|740152780|ref|WP_037997109.1|	32.8	235	316	322	2.67e-32	121
k141_87198_4	SARG|gi|498515089|ref|WP_010815296.1|	35.1	231	316	323	2.72e-32	121
k141_87198_4	SARG|gi|985522333|ref|WP_060811962.1|	35.1	231	316	323	2.72e-32	121
k141_87198_21	CARD|gb|AAD51347.1|ARO:3003067|smeS	32.5	308	383	467	4.27e-46	163
k141_87198_21	CARD|gb|ADM92606.1|ARO:3000549|adeS	32.8	296	383	361	1.69e-37	137
k141_87198_21	megares|MEG_7501|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	27.1	258	383	354	2.20e-21	93.2
k141_87198_21	megares|MEG_7503|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	25.1	307	383	354	2.20e-21	93.2
k141_87198_21	megares|MEG_7500|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	26.7	255	383	352	3.98e-21	92.4
k141_87198_21	megares|MEG_7497|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	26.7	255	383	376	5.12e-21	92.4
k141_87198_21	NCBI|WP_034869172.1|1|1|vanS-C|vanS-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-C|AMR|glycopeptide	26.7	255	383	376	5.12e-21	92.4
k141_87198_21	NCBI|WP_002382867.1|1|1|vanS-B|vanS-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-B|AMR|glycopeptide	25.1	327	383	447	7.70e-19	86.7
k141_87198_21	NCBI|WP_012579101.1|1|1|vanS-B|vanS-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-B|AMR|glycopeptide	25.1	327	383	447	7.70e-19	86.7
k141_87198_21	NCBI|WP_063856739.1|1|1|vanS-B|vanS-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-B|AMR|glycopeptide	25.1	327	383	447	7.70e-19	86.7
k141_87198_22	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	43.9	221	236	228	3.43e-57	180
k141_87198_22	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	42.7	232	236	231	1.21e-55	176
k141_87198_22	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	38.2	228	236	232	2.49e-55	176
k141_87198_22	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	38.2	228	236	232	2.49e-55	176
k141_87198_22	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	41.2	233	236	232	7.99e-54	172
k141_87198_22	CARD|gb|AAG05188.1|ARO:3005068|ParR	38.2	225	236	235	1.26e-50	164
k141_87198_22	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	36.2	229	236	231	5.05e-49	159
k141_87198_22	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	36.2	229	236	231	5.05e-49	159
k141_87198_22	NCBI|WP_222891057.1|1|1|vanR-P|vanR-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-P|AMR|glycopeptide	36.6	232	236	239	1.79e-48	158
k141_87198_22	NCBI|WP_063856721.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	35.8	229	236	231	2.27e-47	155
k141_87198_40	NCBI|WP_063856854.1|1|1|vanY-D|vanY-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D|AMR|glycopeptide	31.5	257	382	356	2.04e-26	107
k141_87198_40	megares|MEG_7603|Drugs|Glycopeptide|VanD-type_accessory_protein|VANYD_1	31.1	251	382	355	2.54e-25	104
k141_87198_40	SARG|BAE96115	31.1	251	382	355	2.54e-25	104
k141_87198_40	megares|MEG_7604|Drugs|Glycopeptide|VanD-type_accessory_protein|VANYD_2	29.6	203	382	209	6.94e-18	80.5
k141_87198_53	megares|MEG_5396|Drugs|Aminocoumarins|Aminocoumarin-resistant_DNA_topoisomerases|PARY_1	42.6	687	640	703	3.66e-177	519
k141_87198_76	CARD|gb|AAC75135.2|ARO:3000792|mdtA	23.8	362	395	415	3.25e-18	84.7
k141_87198_76	SARG|gi|491562557|ref|WP_005420143.1|	24.7	376	395	398	3.35e-16	78.6
k141_87198_76	SARG|YP_001974113	25.7	374	395	398	8.09e-16	77.4
k141_87198_76	SARG|gi|727710352|ref|WP_033833767.1|	25.6	371	395	398	1.95e-15	76.3
k141_87198_76	SARG|AAD51344	25.1	374	395	398	8.42e-15	74.3
k141_87198_76	SARG|gi|491553935|ref|WP_005411526.1|	25.1	371	395	398	1.13e-14	73.9
k141_87198_76	SARG|gi|491557220|ref|WP_005414807.1|	25.1	374	395	398	1.13e-14	73.9
k141_87198_76	SARG|gi|730318750|ref|WP_033983530.1|	24.8	403	395	387	6.16e-14	71.6
k141_87198_76	SARG|gi|730493281|ref|WP_034028540.1|	24.8	403	395	387	8.25e-14	71.2
k141_87198_76	SARG|gi|490482422|ref|WP_004352726.1|	24.8	403	395	387	8.25e-14	71.2
